INTERFACE BIOLOGICS, INC.
Interface Biologics, Inc. (IBI) is a commercial stage company that develops transformative biomedical polymer technology to improve the safety and effectiveness of medical devices. Their patent-protected technologies include anti-thrombogenic additives for blood contacting medical devices and polymer enabled combination drug delivery devices. IBI has exclusive Endexo™ technology licensing agreements with AngioDynamics for vascular access catheters and with Fresenius Medical Care for chronic... dialysis systems. AngioDynamics’ BioFlo PICCS, Ports and DuraMax Dialysis Catheter with IBI’s Endexo technology have received FDA clearance and are gaining commercial traction. IBI also has a joint venture commercial agreement with Qualimed to develop a drug-coated balloon based on IBI’s Kinesyx™ technology. The company was founded in 2001 and is headquartered in Toronto, Canada at the acclaimed MaRS Innovation Centre.
INTERFACE BIOLOGICS, INC.
Social Links:
Industry:
Biotechnology Health Care Medical Device
Founded:
2001-12-01
Address:
Toronto, Ontario, Canada
Country:
Canada
Website Url:
http://www.interfacebiologics.com
Total Employee:
11+
Status:
Active
Contact:
4169771329
Email Addresses:
[email protected]
Total Funding:
32 M USD
Technology used in webpage:
SPF Euro Microsoft Exchange Online Amazon Office 365 Mail GoDaddy DNS Amazon Virginia Region
Similar Organizations
Altaviz
Altaviz develops patent-protected technologies for single-use, custom injection system medical devices.
Aortech International
Aortech International is a biomedical polymer technology, components and medical devices.
Perikinetics
Perikinetics develops an artificial pancreas technology platform to deliver insulin physiologically.
Preciva
Preciva is developing electronic screening tools to give every woman an equal chance to live free of cervical cancer.
Retractable Technologies
Retractable technologies aim to be a catalyst through creativity, education and the production of secure and effective medical devices.
Xillix
Xillix has develops and commercializes medical imaging technologies for detection and localization of cancer.
Current Advisors List
Founder
Investors List
BDC Healthcare Venture
BDC Healthcare Venture investment in Series B - Interface Biologics, Inc.
DSM Venturing
DSM Venturing investment in Series B - Interface Biologics, Inc.
Business Development Bank of Canada
Business Development Bank of Canada investment in Series B - Interface Biologics, Inc.
Covington Group
Covington Group investment in Series B - Interface Biologics, Inc.
BDC Capital Corporation
BDC Capital Corporation investment in Venture Round - Interface Biologics, Inc.
Covington Group
Covington Group investment in Venture Round - Interface Biologics, Inc.
BDC Venture Capital
BDC Venture Capital investment in Seed Round - Interface Biologics, Inc.
Official Site Inspections
http://www.interfacebiologics.com
- Host name: smtp2.innovasium.com
- IP address: 107.21.8.129
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Interface Biologics, Inc."
Interface Biologics - LinkedIn
Interface Biologics is a commercial stage privately held company that develops transformative biomedical polymer technology to improve the safety and effectiveness of medical devices.See details»
Interface Biologics Inc Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Interface Biologics Inc of Toronto, ON. Get the latest business insights from Dun & Bradstreet.See details»
Interface Biologics Company Profile 2024: Valuation, Funding ...
Interface Biologics’s primary industry is Drug Delivery. Is Interface Biologics a private or public company? Interface Biologics is a Private company. What is Interface Biologics’s current …See details»
Interface Biologics, Inc. - Drug pipelines, Patents, Clinical trials ...
Explore Interface Biologics, Inc. with its drug pipeline, therapeutic area, technology platform, .See details»
Interface Biologics - VentureRadar
Interface Biologics is a commercial stage company that develops innovative materials for improving the efficacy of medical devices and targeted delivery of drugs. Our surface …See details»
Interface Bio
At the interface of Human Biology and AI. Complex diseases like autoimmune disorders and cancer require multi-mechanism therapies (e.g. ADCs, bi-specifics), but developing these drugs is challenging due to interaction effects, toxicity, …See details»
Interface Biologics - Overview, News & Similar companies
Nov 26, 2018 Interface Biologics Announces New V.P., Business Development TORONTO, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Interface Biologics Inc. (“IBI”), a privately held, …See details»
Richard Sullivan - President & CEO - Interface Biologics Inc
President & CEO at Interface Biologics Inc. · Experience: Interface Biologics Inc. · Location: Toronto. View Richard Sullivan’s profile on LinkedIn, a professional community of 1 billion …See details»
Interface Biologics | Scientist.com
Interface Biologics 101 College Street Toronto, ON, M5G 1L7 Canada: Get started If your organization has a Scientist.com marketplace, you can log in here to order products and …See details»
This U of T Engineering innovation makes implants …
Sep 3, 2019 In 2001, the additives were part of a suite of innovations used to form the U of T spinoff company, Interface Biologics, Inc. (IBI), based in downtown Toronto. This week, IBI announced that its surface modification …See details»
Interface Biologics Inc. | BDC.ca
Interface Biologics is a privately held early commercial stage company that develops transformative biomedical polymer technology to improve the safety and effectiveness of …See details»
Interface Biologics Announces Sale of Surface Modification …
Sep 3, 2019 “This is an exciting time for our organization”, stated Tom Reeves, President & CEO of Interface Biologics, Inc. “The sale of our Surface Modification business to Evonik is the …See details»
A great leap for Interface Biologics, Inc. - MaRS Discovery District
Since Interface Biologics Inc. (IBI) was founded in 2001, the climb to our success as a company today has been long, but extremely rewarding. And it just got better. Last week, we announced …See details»
Evonik acquires a surface modification technology platform from ...
Sep 3, 2019 “We have been working closely with Evonik on joint development opportunities over the last few years,” said Tom Reeves, President and CEO of Interface Biologics. “I am …See details»
Interface Biologics to focus future growth in biotech with local …
Feb 5, 2019 By Len Zehr. Closely-held Interface Biologics, best known for improving the safety and efficacy of medical devices through its Endexo surface modification technology, is pegging …See details»
Interface Biologics Announces Spinout, Ripple Therapeutics
Interface Biologics (IBI) is an early commercial stage privately held company that develops innovative materials for Medtech applications. IBI surface modification additives are used in …See details»
Ripple Therapeutics
The Ripple Therapeutics' Epidel technology is founded on a discovery that drugs can be engineered into controlled release Pharmaceuticals and Medical Device Coatings without the …See details»
Interface Biosciences - Crunchbase Company Profile & Funding
Interface Biosciences is a platform therapeutics company that specializes in using the microbiome to treat inflammatory diseases.See details»
Quantitative biomimetics of high-performance materials - Nature
1 day ago The ongoing need for materials with difficult-to-combine properties has driven dramatic advancements in the field of bioinspired and biomimetic (nano)structures. These …See details»